Welcome to our dedicated page for Exicure news (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies for hematologic diseases, with a lead focus on the small molecule CXCR4 antagonist burixafor (GPC-100). The Exicure news feed highlights how the company advances this program across multiple indications and how its financial and corporate decisions affect the XCUR stock story.
Readers can follow updates on Exicure’s clinical trials, including an open-label, multicenter Phase 2 study of burixafor in combination with propranolol and G-CSF in patients with multiple myeloma undergoing autologous hematopoietic cell or stem cell transplantation. Company announcements describe topline and interim results, rates of successful CD34+ cell mobilization, engraftment outcomes for participants who proceed to transplant, and safety observations for the burixafor-based regimen.
News items also cover pipeline expansion plans, where Exicure discusses potential use of burixafor in sickle cell disease, rare diseases requiring autologous transplant, cell and gene therapy settings, and as a potential chemosensitizing agent in acute myeloid leukemia (AML). These releases outline how mobilizing hematopoietic or malignant cells from the bone marrow niche into peripheral blood could support transplant procedures or enhance chemotherapy effectiveness.
In addition, the XCUR news stream includes financial results and going concern disclosures, detailing quarterly cash balances, research and development and general and administrative expenses, and management’s assessment that additional financing is needed to fund operations and strategic alternatives. Corporate governance and listing-related developments, such as Nasdaq compliance notices, annual meeting information, and board composition changes, are also reported.
Investors and followers of Exicure can use this page to monitor clinical data presentations, strategic updates related to the acquisition of GPCR Therapeutics USA Inc., and regulatory or capital markets filings that shape the company’s hematology-focused trajectory. Bookmark this feed to review new press releases and regulatory-linked news as they are published.
Exicure, Inc. (NASDAQ: XCUR) has announced a virtual R&D Day on January 7, 2021, from 09:00 am to 10:30 am ET. This event will showcase the company's neuroscience pipeline, particularly its lead program targeting Friedreich’s Ataxia, which has moved into IND-enabling studies. Participants include Dr. Susan Perlman and Jennifer Farmer, who will discuss advancements in the program. Exicure is focused on developing therapeutics using its proprietary SNA technology to address various conditions, including genetic disorders.
Exicure, Inc. (Nasdaq: XCUR) has strengthened its intellectual property portfolio with the issuance of two new patents and the allowance of a patent application related to its therapeutic candidate, cavrotolimod. The new patents (No. 10,792,251 and No. 10,837,018) cover innovative spherical nucleic acid constructs for cancer treatment. CEO David Giljohann expressed enthusiasm about cavrotolimod, currently in Phase 2 clinical trials for Merkel cell carcinoma and cutaneous squamous cell carcinoma, indicating its potential to address unmet medical needs in these rare skin cancers.
Exicure, Inc. (NYSE American:XCUR) will present at the virtual Fall Investor Summit from November 16-18, 2020. This event includes 75 companies and over 300 institutional and retail investors. Exicure focuses on developing nucleic acid-based therapeutics for rare genetic diseases and cancer. Their proprietary spherical nucleic acid (SNA) technology aims to improve drug efficacy across various cells and tissues. The conference connects smallcap and microcap companies with qualified investors, offering a platform for valuable networking.